Spero Therapeutics
SPRO
55 hedge funds and large institutions have $119M invested in Spero Therapeutics in 2019 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 16 increasing their positions, 17 reducing their positions, and 6 closing their positions.
112% more capital invested
Capital invested by funds: $56M → $119M (+$62.6M)
50% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 6
6% more funds holding
Funds holding: 52 → 55 (+3)
0.93% more ownership
Funds ownership: 52.87% → 53.81% (+0.93%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more call options, than puts
Call options by funds: $1K | Put options by funds: $1K
6% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$5.38M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.71M |
| 3 |
Renaissance Technologies
New York
|
+$747K |
| 4 |
AIC
AWM Investment Company
New York
|
+$406K |
| 5 |
BlackRock
New York
|
+$291K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$4.06M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.05M |
| 3 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$1.03M |
| 4 |
FI
Fosun International
Hong Kong,
China
|
-$626K |
| 5 |
State Street
Boston,
Massachusetts
|
-$456K |
SPRO Hedge Fund Activity: Q1 2019 in Review
55 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Spero Therapeutics (SPRO) for Q1 2019, worth a combined $119M — up 112% from $56M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new SPRO positions and 6 closed out — a net gain of 3 holders — while 16 added to existing stakes and 17 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $5.38M. The largest seller was BVF Inc, cutting an estimated $4.06M.
- 55 institutional investors held Spero Therapeutics (SPRO) as of Q1 2019, up from 52 in Q4 2018.
- Funds reported $119M of Spero Therapeutics stock for Q1 2019, up 112% quarter-over-quarter.
- 9 funds opened new Spero Therapeutics positions in Q1 2019 and 6 closed out, a net change of +3 holders.
- The largest Spero Therapeutics buyer in Q1 2019 was OrbiMed, an estimated $5.38M added.
- The largest Spero Therapeutics seller in Q1 2019 was BVF Inc, an estimated $4.06M sold.
Based on aggregated 13F filings for Q1 2019.